In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 628 ( 2022-01-19)
Abstract:
Despite the availability of safe and effective vaccines, SARS-CoV-2 continues to spread globally, contributing to high morbidity and mortality. Current treatments are logistically challenging to provide on a global scale, increasing the need for safe and effective oral therapies. In a randomized, controlled, double-blind, multidose study of the drug molnupiravir in adult outpatients with COVID-19, an 800-mg dose reduced viral RNA more rapidly than placebo and eliminated infectious virus in nasopharyngeal swabs (Fischer et al. ). Molnupiravir was safe and well tolerated. The rapid elimination of infectious virus has important implications for the prevention of SARS-CoV-2 transmission.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abl7430
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022